Provider record
Embody: What We Hold, and What We Have Asked
We hold 1 price record for Embody. All are provider-reported rather than captured by us. Embody has answered none of the four disclosure questions we publish, so most of
We tried to re-read Embody’s own pages on November 20, 2026. The page could not be read that day; the last record we hold, from 2026-10-15, put its lowest compounded tirzepatide figure at $119 a month (12-month prepaid supply ($1,428); $129 one-month sale price (regular $349)). Embody is not scored in our November 20, 2026 computed ranking because joinem.co refused our November 20, 2026 re-read. Sections below that show July 2026 records are kept as dated history.
Why this is a record and not a review
Our provider reviews run to about 2,500 words because we hold enough on those companies to write that much without padding. For Embody we do not. Writing the same length from one uncaptured figure would produce something that reads authoritative and tells you nothing.
So this page publishes exactly what we hold, marks every gap, and states what we have asked for. It becomes a review when there is something to review.
Every record we hold
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Embody | compounded | compounded injectable | — | — | — | — | not captured | third_party | — |
What we have asked, and what is unanswered
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered Pending |
| Clinical oversight and care continuity | 20 pts | — | Not answered Pending |
| State access and operational reliability | 10 pts | — | Not answered Pending |
| Cancellation, billing and support transparency | 10 pts | — | Not answered Pending |
A dash means no figure held. How we grade evidence.
What is missing, and why it matters
The blank cells above are not omissions. Until Embody names its fulfilling pharmacy and registration class, a reader cannot check that pharmacy against a state board or against FDA warning letters, and cannot tell whether the FDA's proposed 503B bulks exclusion affects their supply. Until it publishes an all-in price at a maintenance dose, the figure above describes the start of treatment rather than the cost of it.
Both are things Embody can change in an afternoon, and we publish the answer either way — see the disclosure register.
Questions readers actually ask
Is Embody legitimate?
We have not assessed that. We hold price records and no answers to our disclosure questions, which is not enough to make a judgement in either direction.
How much does Embody cost?
We hold no obtainable figure, and it is provider-reported rather than captured by us. We do not know what it becomes at a maintenance dose.
Which pharmacy does Embody use?
They have not told us. No provider in our dataset has answered that question.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Tirzepatide Cost Without InsurancePillar / Money
- Shed Tirzepatide ReviewProviders
- Questions to Ask a GLP-1 ClinicianTools
Related coverage
Tirzepatide Ranked. “Embody: What We Hold, and What We Have Asked.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/providers/embody/
Quote the capture date beside a figure, not the date you read this page. Why.